<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">EBioMedicine</journal-id><journal-id journal-id-type="iso-abbrev">EBioMedicine</journal-id><journal-title-group><journal-title>EBioMedicine</journal-title></journal-title-group><issn pub-type="epub">2352-3964</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28822719</article-id><article-id pub-id-type="pmc">5605327</article-id><article-id pub-id-type="publisher-id">S2352-3964(17)30324-9</article-id><article-id pub-id-type="doi">10.1016/j.ebiom.2017.08.007</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Thalidomide is Associated With Increased T Cell Activation and Inflammation in Antiretroviral-naive HIV-infected Individuals in a Randomised Clinical Trial of Efficacy and Safety</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vergara</surname><given-names>T&#x000e2;nia R.C.</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Samer</surname><given-names>Sadia</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Santos-Oliveira</surname><given-names>Joanna R.</given-names></name><xref rid="af0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Giron</surname><given-names>Leila B.</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Arif</surname><given-names>Muhammad Shoaib</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Silva-Freitas</surname><given-names>Maria Luciana</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Cherman</surname><given-names>Lia A.</given-names></name><xref rid="af0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Treitsman</surname><given-names>Mauro S.</given-names></name><xref rid="af0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Chebabo</surname><given-names>Alberto</given-names></name><xref rid="af0020" ref-type="aff">d</xref><xref rid="af0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Sucupira</surname><given-names>Maria Cecilia A.</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Da-Cruz</surname><given-names>Alda M.</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Diaz</surname><given-names>Ricardo Sobhie</given-names></name><email>rsdiaz@catg.com.br</email><xref rid="af0005" ref-type="aff">a</xref><xref rid="cr0005" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author"><collab>the SPARC Working Group</collab></contrib></contrib-group><aff id="af0005"><label>a</label>Laborat&#x000f3;rio de Retrovirologia, Universidade Federal de S&#x000e3;o Paulo, S&#x000e3;o Paulo, Brazil</aff><aff id="af0010"><label>b</label>Laborat&#x000f3;rio Interdisciplinar de Pesquisas M&#x000e9;dicas, Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, Brazil</aff><aff id="af0015"><label>c</label>Secretaria Municipal de Sa&#x000fa;de Ant&#x000f4;nio Ribeiro Neto, Rio de Janeiro, Brazil</aff><aff id="af0020"><label>d</label>Oncohiv, Rio de Janeiro, Brazil</aff><aff id="af0025"><label>e</label>Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil</aff><aff id="af0030"><label>f</label>Instituto Federal de Educa&#x000e7;&#x000e3;o, Ci&#x000ea;ncia e Tecnologia do Rio de Janeiro (IFRJ), Rio de Janeiro, Brazil</aff><author-notes><corresp id="cr0005"><label>&#x0204e;</label>Corresponding author at: Rua Pedro de Toledo 669, 6o andar, Vila Clementino, S&#x000e3;o Paulo 04039-032, Brazil.Rua Pedro de Toledo 6696o andarVila ClementinoS&#x000e3;o Paulo04039-032Brazil <email>rsdiaz@catg.com.br</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>12</day><month>8</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>9</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>12</day><month>8</month><year>2017</year></pub-date><volume>23</volume><fpage>59</fpage><lpage>67</lpage><history><date date-type="received"><day>15</day><month>5</month><year>2017</year></date><date date-type="rev-recd"><day>28</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>7</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 The Authors</copyright-statement><copyright-year>2017</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="ab0005"><sec><title>Trial Design</title><p>Open-label, randomised, controlled, pilot proof-of-concept clinical trial.</p></sec><sec><title>Methods</title><p><italic>Participants</italic>: Antiretroviral na&#x000ef;ve adult males with CD4 count &#x02265;&#x000a0;350&#x000a0;cells/mm<sup>3</sup>.</p><p><italic>Interventions</italic>: Patients were randomised to receive thalidomide 200&#x000a0;mg QD for 3&#x000a0;weeks (Thalidomide group) or not (Control group) and followed for 48&#x000a0;weeks.</p><p><italic>Objective</italic>: We hypothesized that short-term Thalidomide use would reduce HIV related inflammation and HIV replication among antiretroviral na&#x000ef;ve HIV infected individuals.</p><p><italic>Outcome</italic>: Viral loads, CD4/CD8 counts, ultra-sensitive C-reactive protein (US-CRP), cell activation markers, and plasma lipopolysaccharide (LPS) were analyzed.</p><p><italic>Randomisation</italic>: Unrestricted randomisation.</p><p><italic>Blinding</italic>: No blinding was used.</p></sec><sec><title>Results</title><p><italic>Numbers randomised</italic>: Thirty recruited individuals were randomised to Thalidomide (16 patients) or Control (14 patients) groups.</p><p><italic>Recruitment</italic>: Patients were recruited from April 2011 to January 2013.</p><p><italic>Outcome</italic>: Viral loads remained stable in both groups. During thalidomide treatment, a decrease in CD4/CD8 ratio (p&#x000a0;=&#x000a0;0.04), a decrease in CD4 count (p&#x000a0;=&#x000a0;0.04), an increase in cell activation calculated by the percentage of CD38 <sup>+</sup>/HLA-DR<sup>+</sup> CD8 cells (p&#x000a0;&#x0003c;&#x000a0;0.05) and an increase in US-CRP (p&#x000a0;&#x0003c;&#x000a0;0.01) were observed in the Thalidomide group, with all parameters returning to baseline levels after thalidomide interruption. We confirmed that thalidomide increased HIV replication <italic>in vitro</italic> of 6 of 7 samples from long-term antiretroviral suppressed individuals.</p><p><italic>Harms</italic>: No class 3/4 adverse events occurred.</p></sec><sec><title>Conclusions</title><p>Short-term use of thalidomide led to an intense transient increase in T cell activation and inflammation, with a decrease in the CD4<sup>+</sup> cell count without changes to the CD8<sup>+</sup> cell count. We confirmed that thalidomide acts <italic>in vitro</italic> as a latency reversal agent and speculate that the <italic>in vivo</italic> results obtained were due to an increase in HIV replication.</p></sec></abstract><abstract abstract-type="author-highlights" id="ab0010"><title>Highlights</title><p><list list-type="simple"><list-item id="li0005"><label>&#x02022;</label><p>Short-term Thalidomide use lead to intense increase in inflammatory markers among HIV+ antiretroviral na&#x000ef;ve individuals.</p></list-item><list-item id="li0015"><label>&#x02022;</label><p>Thalidomide use lead to a transitory decrease in CD4<sup>+</sup> T cells and CD4/CD8 ratios.</p></list-item><list-item id="li0010"><label>&#x02022;</label><p><italic>In vitro</italic> complementary studies revealed that Thalidomide acts as an HIV Latency Reversal Agent.</p></list-item></list></p><p>Thalidomide in general presents a potent anti-inflammatory effect, and is still being used for a number of inflammatory diseases and infection. Therefore, Thalidomide investigated here in a randomised clinical trial aiming to mitigate HIV related inflammation among antiretroviral na&#x000ef;ve individuals. Surprisingly, the HIV related inflammation increased during Thalidomide use, and <italic>in vitro</italic> studies demonstrated that Thalidomide is efficient in interrupting HIV latency, one of the major's obstacles for the cure of HIV chronic infection.</p></abstract><kwd-group id="ks0005"><title>Keywords</title><kwd>Thalidomide</kwd><kwd>T cell activation</kwd><kwd>Inflammation</kwd><kwd>Latency reversal agent</kwd><kwd>HIV</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p>Generalized immune activation and inflammation are hallmarks of the pathogenesis of HIV/AIDS (<xref rid="bb0025" ref-type="bibr">d'Ettorre et al., 2011</xref>). Important factors driving HIV-induced immune activation include ongoing viral replication, microbial translocation from the gastrointestinal (GI) tract and co-infections (<xref rid="bb0105" ref-type="bibr">Marchetti et al., 2013</xref>). Irreversible damage to the integrity of the GI tract's mucosal barrier occurs early during HIV-1 acute infection caused by the irreversible massive depletion of CD4<sup>+</sup> T (memory) cells from the GI tract mucosa, resulting in systemic activation of the immune system <italic>via</italic> the translocation of GI tract microbes and lipopolysaccharide (LPS, as a marker of microbial translocation) across the damaged barrier (<xref rid="bb0105" ref-type="bibr">Marchetti et al., 2013</xref>). New ultrasensitive techniques can detect very low levels of detectable HIV RNA in rectal samples of HIV-infected individuals with undetectable plasma viremia. Despite being on antiretroviral therapy (ART), this ongoing low-level replication at sites such as the GI tract contributes to the disease burden. During ART, microbial translocation declines but does not return to normal levels, indicating the potential role of microbial translocation in HIV-induced immune activation (<xref rid="bb0135" ref-type="bibr">Palmer, 2013</xref>).</p><p>The HIV-induced dysregulation of CD4<sup>+</sup> T regulatory (Treg) cells also results in a permanently over-activated immune system due to the lack of immunomodulation (<xref rid="bb0020" ref-type="bibr">Chevalier and Weiss, 2013</xref>). The overburden of viral gene products together with those of foreign pathogens causes the overactivation of both T and B cells. The non-specific production of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF&#x003b1;), interleukin-1 (IL-1), IL-6 and several others, causes the bystander activation of T and B lymphocytes and ultimately leads to immunosenescence (<xref rid="bb0150" ref-type="bibr">Reeves, 2014</xref>). HIV-1 replication <italic>per se</italic> also relates to immune activation, and the higher the viral load, the higher the immune activation process (<xref rid="bb0060" ref-type="bibr">Hunt et al., 2003</xref>). It has been demonstrated that even defective HIV may produce HIV proteins, which conceivably maintains a state of inflammation in antiretroviral-suppressed individuals (<xref rid="bb0070" ref-type="bibr">Imamichi et al., 2016</xref>). Interestingly, cell activation is higher among HIV-infected elite controllers than among uninfected individuals or antiretroviral-treated individuals with viral loads below detection limits (<xref rid="bb0065" ref-type="bibr">Hunt et al., 2006</xref>).</p><p>This persistent immune activation and inflammation is responsible for enhanced CD4<sup>+</sup> T cell death, lymphoid tissue destruction, kidney and liver problems, atherosclerosis, cardiovascular disease and neurocognitive impairment (<xref rid="bb0150" ref-type="bibr">Reeves, 2014</xref>). Therefore, the future treatment of HIV/AIDS requires the consideration of anti-inflammatory strategies with antivirals to overcome chronic inflammation-associated complications.</p><p>HIV-related immune activation is associated with a rapid and persistent increase in TNF levels (<xref rid="bb0115" ref-type="bibr">McMichael et al., 2010</xref>), resulting in the induction of adhesion molecules and chemokines from the vessel wall (<xref rid="bb0160" ref-type="bibr">Signorelli et al., 2007</xref>), endothelial cell activation and the increased adhesion of leukocytes (<xref rid="bb0130" ref-type="bibr">Mu et al., 2007</xref>).</p><p>One of the drugs known for its immunomodulatory potential is thalidomide.</p><p>Thalidomide has a beneficial effect on skin lesions of leprosy, erythema nodosum leprosum (<xref rid="bb0165" ref-type="bibr">Teo et al., 2002</xref>) and multiple myeloma (<xref rid="bb0015" ref-type="bibr">Chen et al., 2010</xref>). Thalidomide is used in the treatment of various autoimmune or inflammatory disorders, such as Beh&#x000e7;et disease, cutaneous lupus erythematosus, prurigo nodularis, sarcoidosis, chronic graft-<italic>versus</italic>-host disease, and Kaposi's sarcoma (<xref rid="bb0015" ref-type="bibr">Chen et al., 2010</xref>, <xref rid="bb0035" ref-type="bibr">Franks et al., 2004</xref>).</p><p>The pharmacological effects of thalidomide have established it as an anti-inflammatory, immuno-modulatory and anti-angiogenic drug. The mechanisms underlying these features involve the modulation of inflammatory cytokines, such as TNF&#x003b1;, interferon gamma (IFN&#x003b3;), IL-10, IL-12, cyclooxygenase 2 (COX-2) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF&#x003ba;B) (<xref rid="bb0035" ref-type="bibr">Franks et al., 2004</xref>).</p><p>The transcription factor NF&#x003ba;B controls the anti-inflammatory and anti-angiogenic properties of thalidomide. NF&#x003ba;B is located in the cytoplasm in its inactive form bound to the inhibitory protein I&#x003ba;B&#x003b1;. Once stimulated by inducers such as TNF-&#x003b1; or IL-1&#x003b2;, the phosphorylation of I&#x003ba;B&#x003b1; proteins by I&#x003ba;B kinase (IKK) releases NF&#x003ba;B, which translocates to the nucleus and induces the activation of genes responsible for immune and inflammatory responses, cellular proliferation, angiogenesis and the suppression of apoptosis (<xref rid="bb0170" ref-type="bibr">Wang et al., 1999</xref>). Thalidomide exerts its anti-inflammatory effect by enhancing the degradation of TNF-&#x003b1; mRNA, as observed in endotoxin-stimulated monocytes and macrophages (<xref rid="bb0125" ref-type="bibr">Moreira et al., 1993</xref>). In contrast to this anti-TNF activity of thalidomide, IL-2-dependent upregulation of TNF-&#x003b1; by CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes has also been observed <italic>in vitro</italic> (<xref rid="bb0110" ref-type="bibr">Marriott et al., 2002</xref>).</p><p>NF&#x003ba;B is an enhancer of HIV-1 transcription, which, upon the activation of an infected cell, migrates to the nucleus and induces the expression of HIV-1 genes (<xref rid="bb0140" ref-type="bibr">Pomerantz et al., 1990</xref>). Because of the convergence of the regulatory pathways for the transcription of HIV and of cytokine genes, it is possible that interventions directed at limiting the cytokine response to HIV-1 and opportunistic infections could have a profound impact on the replicating HIV-1 levels as well as the associated morbidity and mortality.</p><p>The link between circulating HIV and TNF-&#x003b1; (<xref rid="bb0095" ref-type="bibr">Klausner et al., 1996</xref>) or TNF-&#x003b1; receptors (<xref rid="bb0005" ref-type="bibr">Bilello et al., 1996</xref>) has long been identified in the plasma of infected individuals, and TNF-&#x003b1; induces viral replication <italic>via</italic> a shared NF&#x003ba;B-dependent transcriptional control mechanism (<xref rid="bb0140" ref-type="bibr">Pomerantz et al., 1990</xref>). Targeting TNF-&#x003b1; may reduce viral replication, resulting in lower inflammation. Thalidomide has shown promising results in inhibiting the production of TNF-&#x003b1; both <italic>in vitro</italic> and <italic>in vivo</italic> (<xref rid="bb0155" ref-type="bibr">Sampaio et al., 1993</xref>). These observations have provided the rationale for exploring the anti-inflammatory potential of thalidomide to inhibit TNF-&#x003b1;, thereby reducing HIV replication and associated inflammation.</p><p>The present study was designed to examine whether thalidomide treatment of HIV-1-infected individuals would reduce the levels of HIV surrogate markers of inflammation. We recruited HIV-infected individuals who had not undergone ART, in whom any potential anti-inflammatory properties of thalidomide would be better quantified. We treated these individuals for a period of 3&#x000a0;weeks with thalidomide and followed the patients for 23&#x000a0;weeks. The results were compared to those obtained in a control group consisting of ART-na&#x000ef;ve individuals who remained na&#x000ef;ve throughout the study period.<statement id="en0005"><label>Hypothesis</label><p>We hypothesized that the use of thalidomide would be safe and able to decrease HIV-related inflammation and bacterial translocation. If this hypothesis is confirmed, new trials should include HIV antiretroviral-treated individuals with viral loads below detection limits to further explore the impact of anti-TNF drugs on HIV-1-related inflammatory markers.</p></statement></p></sec><sec id="s0010"><label>2</label><title>Materials and Methods</title><sec id="s0015"><label>2.1</label><title>Study Design and Participants</title><p>This was an open-label, randomised pilot proof-of-concept trial. Thirty individuals were recruited in Rio de Janeiro, Brazil and followed for 23&#x000a0;weeks from April 2011 to January 2013. The subjects were randomly allocated into two groups: the Thalidomide group or Control group (with no thalidomide exposure).</p><p>Patients were ART-na&#x000ef;ve males from 18 to 60&#x000a0;years of age with a body weight &#x02265;&#x000a0;50&#x000a0;kg and CD4<sup>+</sup> T cell counts &#x0003e;&#x000a0;350&#x000a0;cells/mm<sup>3</sup>. The participants were not eligible to begin ART according to local guidelines for the study period. (<ext-link ext-link-type="uri" xlink:href="http://www.aids.gov.br/sites/default/files/consensoAdulto005c_2008montado.pdf" id="ir0005">http://www.aids.gov.br/sites/default/files/consensoAdulto005c_2008montado.pdf</ext-link>)</p><p>Informed consent forms were signed by the participants, and the study protocol was approved by the Ethics Committee and Institutional Review Board at the Universidade Federal de S&#x000e3;o Paulo, Brazil (#17686/09) and Universidade Federal do Rio de Janeiro (#658/10).</p></sec><sec id="s0020"><label>2.2</label><title>Interventions</title><p>Patients were randomised to either receive 100&#x000a0;mg of thalidomide BID for 3&#x000a0;weeks upon study entry (Thalidomide group, 16 patients) or not (Control group, 14 patients); all were followed for 23&#x000a0;weeks. Blood samples were collected for safety tests and HIV monitoring tests, and laboratory work was performed at the Laborat&#x000f3;rio de Retrovirologia of the Universidade Federal de S&#x000e3;o Paulo, Brazil. The cell activation markers were double-checked at the Laborat&#x000f3;rio Interdisciplinar de Pesquisas M&#x000e9;dicas, Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, Brazil.</p></sec><sec id="s0025"><label>2.3</label><title>Sample Size</title><p>As a pilot study, a convenience sample size of 30 patients was determined.</p></sec><sec id="s0030"><label>2.4</label><title>Randomisation</title><p>Unrestricted randomisation. Allocation to distinct groups was determined using blind envelopes.</p></sec><sec id="s0035"><label>2.5</label><title>Clinical and Laboratory Assessments</title><p>Clinical and laboratory assessments were performed at the screening, baseline and at weeks 1, 2, 3, 7, 11, 15, 19, and 23. Patients were evaluated for HIV-1 viral loads, CD4<sup>+</sup> and CD8<sup>+</sup> T cell counts, ultra-sensitive C-reactive protein (US-CRP), CD38 and HLA-DR on CD4<sup>+</sup> and CD8<sup>+</sup> T cells, and LPS quantitation in plasma samples. Blood cell counts and biochemical parameters such as aminotransferase enzymes (ALT and AST), creatinine, and glucose were determined at the screening and at each visit. Electrocardiography was performed at the screening and the last visit.</p><p>Clinical assessment included clinical signs and symptoms related to HIV infection, adverse events, and adherence to thalidomide intake using a predefined questionnaire.</p></sec><sec id="s0040"><label>2.6</label><title>Laboratory Methods</title><sec id="s0045"><label>2.6.1</label><title>Flow Cytometric Evaluation of Cellular Activation</title><p>Peripheral blood mononuclear cells (PBMC) were separated and cryopreserved. After thawing, PBMCs were labeled with anti-CD3 APC and anti-CD4 PercP (for the lymphocytic subpopulation) and anti-CD38 FITC and anti-HLA-DR PE (for cellular activation). Fixed cells were acquired on a FACSCalibur apparatus and analyzed with CellQuest software (BD Biosciences, San Diego CA, USA). The results were expressed as the percentage of CD38<sup>+</sup>&#x000a0;HLA-DR<sup>+</sup> cells among CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes.</p></sec><sec id="s0050"><label>2.6.2</label><title>Assessment of Plasmatic LPS Levels</title><p>Microbial translocation was inferred by plasmatic LPS assessments using QCL-1000 Limulus Amebocyte Lysate (Lonza Walkersville Inc., Walkersville, MD, USA) according to the manufacturer's instructions. The results were expressed as pg/mL, and the minimum limit of detection was 10&#x000a0;pg/mL.</p></sec><sec id="s0055"><label>2.6.3</label><title>Cytokine Measurement</title><p>Cytokine levels were measured in plasma by Cytometric Beads Array kit (CBA, BD Biosciences, San Diego, CA, USA) processed according to the manufacturer's protocol. The following cytokine were quantified: IL-2, IL-4, IL-6, IL-10, IL-17, TNF and IFN-&#x003b3;. A FACSCalibur were used to acquire the samples and data analysis was performed using the software provided by the manufacturer (FCAP Array, BD Biosciences). The standard curve for each cytokine covers a range of 20 to 5000&#x000a0;pg/mL.</p></sec><sec id="s0060"><label>2.6.4</label><title>Determination of CXCR4 and CCR5 Co-receptor Genotropism</title><p>After RNA extraction, reverse transcription nested PCR to amplify the HIV-1 C2V3 region of gp120 and sequencing were carried out as previously described (<xref rid="bb0100" ref-type="bibr">Lavigne et al., 2014</xref>). V3 loop sequences were interpreted to infer co-receptor tropism by web-based genotyping algorithms in Geno2pheno [coreceptor] (<ext-link ext-link-type="uri" xlink:href="http://www.coreceptor.geno2pheno.org" id="ir0010">http://www.coreceptor.geno2pheno.org</ext-link>). Because only one PCR product was subjected to sequencing, in accordance with European guidelines, a false positive rate (FPR) of 10% was used to infer tropism (<xref rid="bb0145" ref-type="bibr">Poveda et al., 2012</xref>), and samples were classified as R5 (FPR&#x000a0;&#x0003e;&#x000a0;10%) or non-R5 (FPR&#x000a0;&#x02264;&#x000a0;10%) tropic.</p></sec><sec id="s0065"><label>2.6.5</label><title>In Vitro Determination of Thalidomide's Effect on the HIV-1 Proviral Compartment</title><p>CD8<sup>+</sup> T-cell depleted PBMCs (EasySep Human CD8 Positive Selection kit, STEMCELL TECHNOLOGIES) isolated from 7 HIV-infected ART-treated patients with undetectable viral loads over a period of two years were used. We measured HIV-1 recovery in <italic>ex vivo</italic> cell cultures first activated by phytohemagglutinin and treated with thalidomide (Sigma Aldrich) for 48&#x000a0;h and then cultured in RPMI medium (Gibco, CA, USA) supplemented with IL-2 20&#x000a0;IU/mL (Roche) and fetal bovine serum (Gibco). Fetal bovine serum was used as the control sample. Supernatant samples were taken at days 3, 7, 10, 14, 17, 21, 24, 28 and 31 and monitored by commercial HIV viral load assay (Abbott RealTime HIV-1 assay, Abbott, Chicago IL).</p></sec></sec><sec id="s0070"><label>2.7</label><title>Statistical Analyses</title><p>The Mann-Whitney <italic>U</italic> test, Student's <italic>t</italic>-test, analysis of variance (ANOVA), and the Kruskal-Wallis test with Dunn's <italic>post hoc</italic> test were used for comparisons between groups. Spearman's test was used to perform correlations between different parameters. GraphPad Prism version 5.0 for Windows (GraphPad Software, San Diego, CA, USA) was employed for the analyses.</p></sec></sec><sec id="s0075"><label>3</label><title>Results</title><sec id="s0080"><label>3.1</label><title>Patients' Dispositions, Baseline Characteristics and Virologic/Immunologic Response to Therapy</title><p>The participant's Flow chart is described in <xref rid="f0005" ref-type="fig">Fig. 1</xref>. Thalidomide-treated patients and control patients were comparable in terms of age, T cell counts and HIV viral load at the beginning of the study (<xref rid="t0005" ref-type="table">Table 1</xref>). One patient in the Thalidomide group was co-infected with HCV, and one patient in the Control group was co-infected with HBV.<fig id="f0005"><label>Fig. 1</label><caption><p>Participant's flowchart.</p></caption><alt-text id="al0005">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig><table-wrap id="t0005" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the thalidomide and control groups.</p></caption><alt-text id="al0040">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Characteristics</th><th>Thalidomide</th><th>Control</th><th>p-Value</th></tr></thead><tbody><tr><td>N</td><td>16</td><td>14</td><td/></tr><tr><td>Age (&#x000b1;&#x000a0;SD)</td><td>36.88 (&#x000b1;&#x000a0;9.28)</td><td>31.36 (&#x000b1;&#x000a0;5.47)</td><td>0.16</td></tr><tr><td>Viral load log10</td><td/><td/><td/></tr><tr><td>&#x000a0;Mean (&#x000b1;&#x000a0;SD)</td><td>3.67 (&#x000b1;&#x000a0;1.33)</td><td>3.82 (&#x000b1;&#x000a0;0.57)</td><td>0.59</td></tr><tr><td>&#x000a0;Median</td><td>4.11</td><td>3.75</td><td/></tr><tr><td>&#x000a0;IQR</td><td>3.83&#x02013;4.62</td><td>3.46&#x02013;4.21</td><td/></tr><tr><td>CD4<sup>+</sup> T cells/mm<sup>3</sup></td><td/><td/><td/></tr><tr><td>&#x000a0;Mean (&#x000b1;&#x000a0;SD)</td><td>623 (&#x000b1;&#x000a0;231)</td><td>605 (&#x000b1;&#x000a0;255)</td><td>0.93</td></tr><tr><td>&#x000a0;Median</td><td>602</td><td>625</td><td/></tr><tr><td>&#x000a0;IQR</td><td>468&#x02013;660</td><td>388&#x02013;716</td><td/></tr><tr><td>CD8<sup>+</sup> T cells/mm<sup>3</sup></td><td/><td/><td/></tr><tr><td>&#x000a0;Mean (&#x000b1;&#x000a0;SD)</td><td>1162 (&#x000b1;&#x000a0;396)</td><td>1014 (&#x000b1;&#x000a0;360)</td><td>0.57</td></tr><tr><td>&#x000a0;Median</td><td>1117</td><td>1061</td><td/></tr><tr><td>&#x000a0;IQR</td><td>865&#x02013;1383</td><td>734&#x02013;1278</td><td/></tr><tr><td>CD4/CD8 ratio</td><td/><td/><td/></tr><tr><td>&#x000a0;Mean (&#x000b1;&#x000a0;SD)</td><td>0.58 (&#x000b1;&#x000a0;0.23)</td><td>0.67 (&#x000b1;&#x000a0;0.36)</td><td>0.77</td></tr><tr><td>&#x000a0;Median</td><td>0.55</td><td>0.52</td><td/></tr><tr><td>&#x000a0;IQR</td><td>0.38&#x02013;0.71</td><td>0.41&#x02013;0.85</td><td/></tr><tr><td>CD4/CD38/HLA-DR</td><td/><td/><td/></tr><tr><td>&#x000a0;Mean (&#x000b1;&#x000a0;SD)</td><td>7.10 (&#x000b1;&#x000a0;4.7)</td><td>5.98 (&#x000b1;&#x000a0;3.42)</td><td>0.75</td></tr><tr><td>&#x000a0;Median</td><td>5.64</td><td>5.68</td><td/></tr><tr><td>&#x000a0;IQR</td><td>2.82&#x02013;12.1</td><td>3.18&#x02013;7.36</td><td/></tr><tr><td>CD8/CD38/HLA-DR</td><td/><td/><td/></tr><tr><td>&#x000a0;Mean (&#x000b1;&#x000a0;SD)</td><td>20.41 (&#x000b1;&#x000a0;13.6)</td><td>20.07 (&#x000b1;&#x000a0;8.8)</td><td>0.93</td></tr><tr><td>&#x000a0;Median</td><td>18.32</td><td>16.72</td><td/></tr><tr><td>&#x000a0;IQR</td><td>7.73&#x02013;32.74</td><td>13.90&#x02013;24.25</td><td/></tr><tr><td>US-PCR mg/dL</td><td/><td/><td/></tr><tr><td>&#x000a0;Mean (&#x000b1;&#x000a0;SD)</td><td>2.70 (&#x000b1;&#x000a0;1.6)</td><td>2.15 (&#x000b1;&#x000a0;1.09)</td><td>0.45</td></tr><tr><td>&#x000a0;Median</td><td>2.72</td><td>2.03</td><td/></tr><tr><td>&#x000a0;IQR</td><td>1.34&#x02013;4.28</td><td>1.21&#x02013;3,07</td><td/></tr><tr><td>LPS level pg/mL</td><td/><td/><td/></tr><tr><td>&#x000a0;Mean (&#x000b1;&#x000a0;SD)</td><td>59.51 (&#x000b1;&#x000a0;28,7)</td><td>46.59 (&#x000b1;&#x000a0;21.7)</td><td>0.30</td></tr><tr><td>&#x000a0;Median</td><td>51.05</td><td>42.9</td><td/></tr><tr><td>&#x000a0;IQR</td><td>35.15&#x02013;79.03</td><td>30.70&#x02013;66.70</td><td/></tr><tr><td>B subtype</td><td/><td/><td/></tr><tr><td>R5</td><td>8</td><td>11</td><td/></tr><tr><td>Change of tropism</td><td>0/8</td><td>4/11</td><td/></tr></tbody></table></table-wrap></p><p>Adherence was measured weekly using a predefined questionnaire, and the pill count indicated 100% thalidomide use. One patient stopped the medication on day 16 due to a mild cutaneous rash that disappeared upon thalidomide interruption. There were no grade 3 or 4 adverse events during thalidomide use (<xref rid="t0010" ref-type="table">Table 2</xref>).<table-wrap id="t0010" position="float"><label>Table 2</label><caption><p>Adverse events during the clinical trial period. No grade 3 and 4 adverse events were detected.</p></caption><alt-text id="al0045">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Thalidomide group</th><th>Week 1<hr/></th><th>Week 2<hr/></th><th>Week 3<hr/></th><th>Week 7<hr/></th><th>Week 15<hr/></th><th>Week 21<hr/></th><th>Week 23<hr/></th></tr><tr><th>N</th><th>N</th><th>N</th><th>N</th><th>N</th><th>N</th><th>N</th></tr></thead><tbody><tr><td>Probably unrelated to thalidomide</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Syphilis</td><td/><td>1</td><td/><td/><td>1</td><td/><td/></tr><tr><td>&#x000a0;HPV</td><td/><td/><td/><td/><td>1</td><td/><td/></tr><tr><td>Possibly unrelated to thalidomide</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Diarrhea</td><td>1</td><td/><td/><td/><td/><td>1</td><td/></tr><tr><td>&#x000a0;Common cold symptoms</td><td/><td>3</td><td>2<xref rid="tf0005" ref-type="table-fn">&#x0204e;</xref></td><td>2<xref rid="tf0005" ref-type="table-fn">&#x0204e;</xref></td><td>1<xref rid="tf0005" ref-type="table-fn">&#x0204e;</xref></td><td/><td/></tr><tr><td>&#x000a0;Infectious gastroenteritis</td><td/><td>1</td><td>1<xref rid="tf0005" ref-type="table-fn">&#x0204e;</xref></td><td/><td/><td/><td/></tr><tr><td>&#x000a0;Sinusitis</td><td/><td/><td>1</td><td/><td/><td/><td/></tr><tr><td>&#x000a0;Furunculosis</td><td/><td/><td/><td/><td/><td>1</td><td/></tr><tr><td>&#x000a0;Intestinal constipation</td><td/><td/><td>1</td><td/><td/><td/><td/></tr><tr><td>Possibly related to thalidomide</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Somnolence</td><td>12</td><td>10</td><td>9</td><td/><td/><td/><td/></tr><tr><td>&#x000a0;Skin rash</td><td/><td/><td>1</td><td/><td/><td/><td/></tr><tr><td>&#x000a0;Dry mouth</td><td/><td/><td>1</td><td/><td/><td/><td/></tr><tr><td>&#x000a0;Dry skin</td><td/><td>1</td><td>1</td><td/><td/><td/><td/></tr><tr><td>Control group</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Gingivitis</td><td>1</td><td>1<xref rid="tf0005" ref-type="table-fn">&#x0204e;</xref></td><td>1<xref rid="tf0005" ref-type="table-fn">&#x0204e;</xref></td><td>1<xref rid="tf0005" ref-type="table-fn">&#x0204e;</xref></td><td>1<xref rid="tf0005" ref-type="table-fn">&#x0204e;</xref></td><td>1<xref rid="tf0005" ref-type="table-fn">&#x0204e;</xref></td><td/></tr><tr><td>&#x000a0;Cold</td><td/><td/><td>1</td><td/><td>1</td><td/><td>1<xref rid="tf0005" ref-type="table-fn">&#x0204e;</xref></td></tr><tr><td>&#x000a0;Dental abscess</td><td/><td/><td/><td/><td>1</td><td>1<xref rid="tf0005" ref-type="table-fn">&#x0204e;</xref></td><td/></tr><tr><td>&#x000a0;Tonsillitis</td><td/><td/><td/><td/><td>1</td><td/><td/></tr><tr><td>&#x000a0;Syphilis</td><td/><td/><td/><td/><td>1</td><td/><td/></tr><tr><td>&#x000a0;Gonorrhea</td><td/><td/><td/><td/><td>1</td><td/><td/></tr></tbody></table><table-wrap-foot><fn id="tf0005"><label>&#x0204e;</label><p id="np0005">Patient presented the same symptoms at subsequent visit. N&#x000a0;=&#x000a0;number of patients.</p></fn></table-wrap-foot></table-wrap></p><p>The mean baseline viral loads were 3.67 (range: &#x0003c;&#x000a0;2.6&#x02013;4.85) and 3.82 (range: 2.93&#x02013;4.95) log<sub>10</sub> HIV-1 RNA copies/mL for the Thalidomide and Control groups, respectively (<xref rid="t0005" ref-type="table">Table 1</xref>). A non-significant increase in viral load was observed in Thalidomide group during the three weeks of thalidomide therapy; the mean viral load increased from 3.67 to 3.83 log<sub>10</sub> HIV-1 RNA copies/mL, returning to baseline values after thalidomide withdrawal (Supplemental Table 1). At week 23, the mean viral loads were 3.65 (range: &#x0003c;&#x000a0;50&#x02013;5.67) and 4.06 (range: 3.38&#x02013;5.04) log<sub>10</sub> copies/mL for the Thalidomide and Control groups, respectively (Supplemental Tables 1 and 2). One patient (TV13) in the Thalidomide group was an elite controller, and at week 8, detectable viremia of 67 (1.83 log<sub>10</sub>) copies/mL was observed, which returned to undetectable levels in subsequent visits (Supplemental Table 1).</p><p>The screening mean CD4<sup>+</sup> T cell count was 623&#x000a0;cells/mm<sup>3</sup>&#x000a0;&#x000b1;&#x000a0;230 (median: 602&#x000a0;cells/mm<sup>3</sup>, IQR: 468&#x02013;660&#x000a0;cells/mm<sup>3</sup>) and 605&#x000a0;cells/mm<sup>3</sup>&#x000a0;&#x000b1;&#x000a0;255 (median: 625&#x000a0;cells/mm<sup>3</sup>, IQR: 388&#x02013;716&#x000a0;cells/mm<sup>3</sup>) for the Thalidomide and Control groups, respectively. Declines in the CD4<sup>+</sup> T cell count (p&#x000a0;=&#x000a0;0.04) and the CD4/CD8 ratio (p&#x000a0;=&#x000a0;0.05) were observed during thalidomide use in the Thalidomide group, returning to baseline levels after drug withdrawal (<xref rid="f0010" ref-type="fig">Fig. 2</xref>) (Supplemental Tables 1 and 2). During the study period, the CD4<sup>+</sup> T cell count of four patients (TV03, 11, 29 and 31) in the Thalidomide group and one patient (TV12) in the Control group declined to &#x0003c;&#x000a0;350&#x000a0;cells/mm<sup>3</sup> (were excluded from the subsequent analysis, as they initiated ART (Fisher's exact test: p&#x000a0;=&#x000a0;0.6)).<fig id="f0010"><label>Fig. 2</label><caption><p>Ratio of CD4<sup>+</sup> T cell counts and CD4/CD8<sup>+</sup> T cell counts over time among groups of Thalidomide and Control patients. Peripheral blood from patient of all groups was collected at each visit during 24&#x000a0;weeks for the absolute quantification of CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes by flow cytometry. The closed symbols relate to absolute CD4<sup>+</sup> T cell counts, and open symbols relate to the CD4/CD8<sup>+</sup> ratio. The results are expressed as the mean&#x000a0;&#x000b1;&#x000a0;standard deviation. N&#x000a0;=&#x000a0;number of participants.</p></caption><alt-text id="al0010">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig></p><p>The overall screening mean CD8<sup>+</sup> T cell counts were 1162&#x000a0;&#x000b1;&#x000a0;396&#x000a0;cells/mm<sup>3</sup> (median: 1117&#x000a0;cells/mm<sup>3</sup>, IQR: 865&#x02013;1383&#x000a0;cells/mm<sup>3</sup>) and 1014&#x000a0;&#x000b1;&#x000a0;360&#x000a0;cells/mm<sup>3</sup> (median: 1061&#x000a0;cells/mm<sup>3</sup>, IQR: 734&#x02013;1278&#x000a0;cells/mm<sup>3</sup>) for the Thalidomide and Control groups, respectively. No significant change in the CD8<sup>+</sup> T cell count was detected in either group (<xref rid="t0005" ref-type="table">Table 1</xref>, Supplemental Tables 1 and 2).</p><p>As seen in <xref rid="f0015" ref-type="fig">Fig. 3</xref>, the mean Leucocytes count in the Thalidomide group was 6577.33&#x000a0;cells/mL as compared to 5402&#x000a0;cells/mL at week 23 (p&#x000a0;=&#x000a0;0.03), and mean lymphocytes counts was 2283.79&#x000a0;cells/mL at baseline and 1842&#x000a0;cells/mL at week 23 (p&#x000a0;=&#x000a0;0.001), whereas the mean Leucocytes in the Control group were 5610.77 and 5653.08&#x000a0;cells/mL at baseline and week 23 respectively (p&#x000a0;=&#x000a0;0.9), and mean lymphocytes counts were 1973.54 and 1009.92&#x000a0;cells/mL at baseline and week 23 respectively (p&#x000a0;=&#x000a0;0.7).<fig id="f0015"><label>Fig. 3</label><caption><p>Leukocytes and Lymphocytes count at baseline and at the end of the study. Results are shown for the Thalidomide group (panels A and B respectively), and the control group (panels C and D respectively), and statistical analysis was performed using Pared parametric <italic>t</italic>-test.</p></caption><alt-text id="al0015">Fig. 3</alt-text><graphic xlink:href="gr3"/></fig></p></sec><sec id="s0085"><label>3.2</label><title>Thalidomide was Accompanied by Increased Inflammation and Cell Activation Levels</title><p>At study onset, the levels of CD4<sup>+</sup>- or CD8<sup>+</sup>-activated T lymphocytes, as inferred by the percentages of cells expressing CD38 and HLA-DR, were similar in both groups, as shown in <xref rid="t0005" ref-type="table">Table 1</xref>.</p><p>Counterintuitively, the Thalidomide group presented an increased cell activation status inferred by the percentage of CD38<sup>+</sup>/HLA-DR<sup>+</sup> CD4<sup>+</sup> cells and the CD8<sup>+</sup> T cell counts (p&#x000a0;&#x0003c;&#x000a0;0.05). This analysis was repeated in the two participating laboratories at UNIFESP and FIOCRUZ, and the results were consistent (<xref rid="f0020" ref-type="fig">Fig. 4</xref>). In the elite controller patient, the percentage of CD38/HLA-DR<sup>+</sup> on CD8<sup>+</sup> cells increased during the thalidomide period from 3.2% to 11.3% after 3&#x000a0;weeks of thalidomide and then decreasing to 2.2, 2.4 and 1.8% at weeks 8, 12 and 20, respectively. No activation of CD4<sup>+</sup> T cells was observed (data on file).<fig id="f0020"><label>Fig. 4</label><caption><p>T cell activation status over time among the Thalidomide and Control groups. Peripheral blood mononuclear cells (PBMC) from patients of all groups were obtained by Ficoll-Hypaque gradient centrifugation. PBMC were thawed and used for immunophenotyping at the pre-established periods over 24&#x000a0;weeks. The percentages of CD38<sup>+</sup>/HLA-DR<sup>+</sup> CD4<sup>+</sup> T cells (2A) and CD8<sup>+</sup> T cells (2B) are expressed as the mean&#x000a0;&#x000b1;&#x000a0;standard deviation (Panel A) and median (Panel B). The Thalidomide group showed an increased cell activation status compared to the Control group (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05). Thalidomide intake began in week 1 and was completed at the end of week 3. Patients were followed up until the end of week 23.</p></caption><alt-text id="al0020">Fig. 4</alt-text><graphic xlink:href="gr4"/></fig></p><p>Furthermore, an increase in the unspecific inflammatory marker US-CRP was also detected in the Thalidomide group exclusively during the thalidomide intake period (<xref rid="f0025" ref-type="fig">Fig. 5</xref>, p&#x000a0;=&#x000a0;0.004). All 30 enrolled volunteers showed a US-CRP level above 0.1&#x000a0;mg/dL during the screening visit; this level was above 1&#x000a0;mg/dL in 88% of the Thalidomide group and 86% of the Control group.<fig id="f0025"><label>Fig. 5</label><caption><p>Inflammatory status over time in the Thalidomide group and Control group inferred by the levels of ultra-sensitive C-reactive protein (US-CRP) were assessed in the patients plasma by colorimetric assay. The levels are expressed as medians.</p></caption><alt-text id="al0025">Fig. 5</alt-text><graphic xlink:href="gr5"/></fig></p><p>In relation to LPS levels, there was no significant baseline difference between the Thalidomide group (mean: 59.5&#x000a0;&#x000b1;&#x000a0;28.7&#x000a0;pg/mL) and Control group (mean: 46.6&#x000a0;&#x000b1;&#x000a0;21.7&#x000a0;pg/mL). However, a non-statically significant increase in the LPS levels was observed in the Thalidomide group during thalidomide intake with a reduction in the levels observed at subsequent visits.</p><sec id="s0090"><label>3.2.1</label><title>Additional Correlations</title><p>There was also a positive correlation between T cell activation and viral load, demonstrated in both the percentage of CD38/HLA-DR<sup>+</sup> CD8<sup>+</sup> cells and the CD4<sup>+</sup> T cell counts in both the Thalidomide and Control groups (p&#x000a0;=&#x000a0;0.001, Supplemental Fig. 1). Interestingly, the increase in LPS level was accompanied by an increase in the US-CPR level in the Thalidomide group (p&#x000a0;=&#x000a0;0.05, Supplemental Fig. 2). Interestingly, there was an apparent increase in the TNF levels in some individuals on the Thalidomide arm as compared to the control arm when comparing baseline levels to the levels encountered on the last day of Thalidomide intake (<xref rid="f0030" ref-type="fig">Fig. 6</xref>). However, no statistical significance in the mean and median TNF levels between different time points in each group. No statistical difference was detected in the other cytokine levels related to the period of Thalidomide intake (data on file).<fig id="f0030"><label>Fig. 6</label><caption><p>Levels of TNF in the Thalidomide arm and control arm. Despite the apparent increase in the TNF levels in some individuals on the Thalidomide arm as compared to the control arm when comparing baseline levels to the levels encountered on the last day of Thalidomide intake, no statistical significance in the mean and median TNF levels between different time points in each group was observed.</p></caption><alt-text id="al0030">Fig. 6</alt-text><graphic xlink:href="gr6"/></fig></p></sec></sec><sec id="s0095"><label>3.3</label><title>HIV Evolution Vis a Vis Co-receptor Tropism</title><p>To understand the changes in the CD4<sup>+</sup> T cell count during thalidomide therapy and the possible link with the HIV-1 subtype or co-receptor used, co-receptor tropism was assessed from plasma RNA. Initially, co-receptor tropism was assessed at screening and week 24. In case of amplification failure and/or detection of non-R5 viruses, intermediate collection time points were also analyzed. Amino acid alignments of the HIV-1 envelope V3 loops along with their inferred viral tropism and subtypes are shown in Supplemental Figs. 3 and 4. The co-receptor tropism of both groups at successive visits is shown in <xref rid="t0015" ref-type="table">Table 3</xref>. No significant differences were observed in either group in terms of viral load and CD4<sup>+</sup> and CD8<sup>+</sup> T cell counts on the basis of the tropism profiles (data on file).<table-wrap id="t0015" position="float"><label>Table 3</label><caption><p>HIV-1 and V3 co-receptor tropism of the Thalidomide group at successive visits inferred through Geno2pheno with an FPR set at 10%. -: HIV-1 env V3 region amplification failed or co-receptor tropism not determined.</p></caption><alt-text id="al0050">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th>ID</th><th>Screening</th><th>Baseline</th><th>Week 1</th><th>Week 2</th><th>Week 3</th><th>Week 7</th><th>Week 11</th><th>Week 17</th><th>Week 19</th><th>Week 23</th></tr></thead><tbody><tr><td rowspan="16">Thalidomide</td><td>TV01</td><td>R5</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>TV03</td><td>&#x02013;</td><td>X4</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>X4</td></tr><tr><td>TV05</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>TV07</td><td>R5</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td></tr><tr><td>TV09</td><td>&#x02013;</td><td>R5</td><td>R5</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td><td>R5</td><td>R5</td><td>R5</td></tr><tr><td>TV11</td><td>R5</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td></tr><tr><td>TV13</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>TV15</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>TV21</td><td>R5</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td></tr><tr><td>TV23</td><td>R5</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td></tr><tr><td>TV25</td><td>R5</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td></tr><tr><td>TV27</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>X4</td><td>X4</td></tr><tr><td>TV29</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>TV31</td><td>R5</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td><td>&#x02013;</td></tr><tr><td>TV33</td><td>&#x02013;</td><td>X4</td><td>X4</td><td>X4</td><td>X4</td><td>X4</td><td>X4</td><td>X4</td><td>&#x02013;</td><td>X4</td></tr><tr><td>TV37</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td></tr><tr><td rowspan="14">Control</td><td>TV02</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td><td>R5</td><td>R5</td><td>R5</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td></tr><tr><td>TV06</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td><td>R5</td><td>R5</td><td>R5</td><td>R5</td><td>X4</td><td>&#x02013;</td><td>X4</td></tr><tr><td>TV08</td><td>&#x02013;</td><td>&#x02013;</td><td>X4</td><td>X4</td><td>X4</td><td>X4</td><td>X4</td><td>R5</td><td>X4</td><td>X4</td></tr><tr><td>TV12</td><td>&#x02013;</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>TV14</td><td>&#x02013;</td><td>X4</td><td>&#x02013;</td><td>X4</td><td>X4</td><td>X4</td><td>X4</td><td>&#x02013;</td><td>X4</td><td>&#x02013;</td></tr><tr><td>TV16</td><td>&#x02013;</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td><td>&#x02013;</td><td>R5</td><td>&#x02013;</td></tr><tr><td>TV18</td><td>&#x02013;</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td></tr><tr><td>TV20</td><td>R5</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td></tr><tr><td>TV22</td><td>R5</td><td>R5</td><td>R5</td><td>R5</td><td>R5</td><td>R5</td><td>R5</td><td>X4</td><td>&#x02013;</td><td>X4</td></tr><tr><td>TV24</td><td>R5</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td></tr><tr><td>TV28</td><td>R5</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td></tr><tr><td>TV32</td><td>R5</td><td>R5</td><td>X4</td><td>&#x02013;</td><td>R5</td><td>R5</td><td>X4</td><td>&#x02013;</td><td>X4</td><td>X4</td></tr><tr><td>TV34</td><td>R5</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td></tr><tr><td>TV36</td><td>R5</td><td>R5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>R5</td></tr></tbody></table></table-wrap></p><p>As shown in <xref rid="t0015" ref-type="table">Table 3</xref>, a change/switch in co-receptor tropism was not observed in 7 individuals in the Thalidomide group harboring R5 viruses at the final visit of the study period. However, in the Control group, 3 out of 12 patients switched to using CXCR4 during the study period (Fisher exact test, <italic>p</italic>&#x000a0;=&#x000a0;0.2). HIV-1 subtypes and the co-receptor tropism profiles of the individuals were not found to influence the changes in CD4<sup>+</sup> T cell counts observed in our study. The observed changes in CD4<sup>+</sup> T cell counts were therefore an effect of thalidomide therapy (<xref rid="t0015" ref-type="table">Table 3</xref>).</p></sec><sec id="s0100"><label>3.4</label><title>The In Vitro Effect of Thalidomide on HIV-infected Cells</title><p>The altered laboratory values detected in the Thalidomide group returned to baseline levels after thalidomide withdrawal. Although safe, the short-term use of thalidomide among ART-na&#x000ef;ve individuals led to a counter-intuitive intense transitory increase in T cell activation and inflammation, with a decrease in CD4<sup>+</sup> T cells without a detectable change in CD8<sup>+</sup> T cells and viral loads, although it is inherently difficult to detect changes in viral load among naturally viremic individuals. We therefore asked whether these results might be related to the potential purging activity of thalidomide.</p><p>Samples from 7 individuals not participating in this study and under ART with viral loads below the detection limits for a mean period of 10.4&#x000a0;years (from 2.1 to 18.2&#x000a0;years) were collected, and CD8<sup>+</sup> T cells depleted of other PBMCs were used. Thalidomide treatment induced purging in 6 out of 7 samples (<xref rid="f0035" ref-type="fig">Fig. 7</xref>). On the second day after treatment with thalidomide, the culture supernatants were tested for viral load using qPCR, and the results revealed HIV-1 emergence at day 4 with a change in viral load from 2.2 <sub>log10</sub> to 6.0 <sub>log10</sub> (median of 5.7 <sub>log10</sub>) HIV-1 RNA copies/mL, whereas viruses were not detected in control samples (<xref rid="t0020" ref-type="table">Table 4</xref>). Relating viral emergence with clinical parameters showed that culture positivity was independent of the CD4<sup>+</sup> T cell nadir, the time of viral load below detection limits, the antiretroviral scheme, viral tropism and the subtype of virus (data on file), reinforcing the role of thalidomide in this phenomenon.<fig id="f0035"><label>Fig. 7</label><caption><p>The <italic>in vitro</italic> effect of Thalidomide on increase in viral load from PBMCs samples from seven patients on undetectable viral load. PBMCs were activated with Thalidomide in the presence of Phytohaemagglutinin and IL-2 for 48&#x000a0;h. Viral RNA was quantified by qPCR. Y-axis shows HIV-1 RNA (log<sub>10</sub> copies/ml). X-axis shows the days at which supernatants were collected for viral RNA quantification. Symbol TA indicates patient ID.</p></caption><alt-text id="al0035">Fig. 7</alt-text><graphic xlink:href="gr7"/></fig><table-wrap id="t0020" position="float"><label>Table 4</label><caption><p>Viral load in the culture supernatants from thalidomide-treated samples. Subjects with viral rebound after drug treatment are highlighted. C&#x000a0;=&#x000a0;Supernatant collection; VL&#x000a0;=&#x000a0;Viral load (copies/mL); BDL&#x000a0;=&#x000a0;Viral load below detection limits.</p></caption><alt-text id="al0055">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th>ID</th><th>Day</th><th>VL</th><th>Day</th><th>VL</th><th>Day</th><th>VL</th><th>Day</th><th>VL</th><th>Day</th><th>VL</th></tr></thead><tbody><tr><td>TA1</td><td>0</td><td>&#x0003c;&#x000a0;50</td><td>4</td><td>459</td><td>7</td><td>462</td><td>11</td><td>1378169</td><td>14</td><td>8469592</td></tr><tr><td>TA2</td><td>0</td><td>&#x0003c;&#x000a0;50</td><td>4</td><td>3740</td><td>7</td><td>13,091</td><td>11</td><td>&#x0003e;&#x000a0;10,000,000</td><td>14</td><td>&#x0003e;&#x000a0;10,000,000</td></tr><tr><td>TA3</td><td>0</td><td>&#x0003c;&#x000a0;50</td><td>4</td><td>522</td><td>7</td><td>318</td><td>11</td><td>BDL</td><td>14</td><td>BDL</td></tr><tr><td>TA4</td><td>0</td><td>&#x0003c;&#x000a0;50</td><td>4</td><td>478</td><td>7</td><td>BDL</td><td>11</td><td>BDL</td><td>14</td><td>BDL</td></tr><tr><td>TA5</td><td>0</td><td>&#x0003c;&#x000a0;50</td><td>4</td><td>6009</td><td>7</td><td>1685</td><td>11</td><td>1230</td><td>14</td><td>1047</td></tr><tr><td>TA6</td><td>0</td><td>&#x0003c;&#x000a0;50</td><td>4</td><td>BDL</td><td>7</td><td>BDL</td><td>11</td><td>BDL</td><td>14</td><td>BDL</td></tr><tr><td>TA7</td><td>0</td><td>&#x0003c;&#x000a0;50</td><td>4</td><td>4191</td><td>7</td><td>1992</td><td>11</td><td>6610</td><td>14</td><td>71792</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="s0105"><label>4</label><title>Discussion</title><p>In this study, we explored the effects of thalidomide among ART-na&#x000ef;ve HIV-infected individuals with stable CD4<sup>+</sup> T cell levels for the short period of three weeks in comparison to an equivalent control group, both to be followed by a period of 23&#x000a0;weeks. As a potent TNF-&#x003b1; inhibitor, our hypothesis was that thalidomide use would be safe and able to mitigate one of the major changes associated with chronic HIV infection: HIV-related inflammation. We also hypothesized that in the absence of antiretroviral medications, the anti-inflammatory thalidomide effect would become more evident. Thus, we carefully monitored HIV-related inflammatory markers, such as T cell activation, unspecific inflammatory markers, such as US-CRP, and bacterial translocation markers, such as plasmatic LPS levels, in addition to viral loads and CD4<sup>+</sup> and CD8<sup>+</sup> T cell counts.</p><p>The basis of our hypothesis in this study was that TNF-&#x003b1; can trigger the cytokine production cascade by inducing cytokine secretion by target cells. TNF-&#x003b1; acts by activating the cellular transcription factor NF-kB, which induces the expression of cytokines and other cellular genes (<xref rid="bb0010" ref-type="bibr">Breen, 2002</xref>). TNF-&#x003b1; can bind to two membrane receptors on target cells, TNF receptor 1 (TNFR1, also known as TNFRSF1A and p55) or TNF receptor 2 (TNFR2, also known as TNFRSF1B and p75), to activate two distinct intracellular signaling pathways for gene transcription (<xref rid="bb0030" ref-type="bibr">Faustman and Davis, 2010</xref>). TNFR1 is present in almost all cells of the body, and its signaling induces the cascade related to apoptosis. TNF binding to TNFR1 activates apoptosis through two pathways involving the adaptor proteins TNFR1-associated death domain (TRADD) and Fas-associated death domain (FADD). TNFR2 is related to T cell survival, and its signaling involves the mobilization of the transcription factor NF-kB to promote the transcription of pro-survival genes. NF-&#x003ba;B contributes to a variety of components of the immune system through its role in the development and differentiation of immune cells and lymphoid organs. NF-&#x003ba;B's strongest inducers are the cytokines TNF and IL-1, as well as pathogen-derived LPS.</p><p>Surprisingly, however, we were able to document that T cell activation markedly increased in both CD4<sup>+</sup> and CD8<sup>+</sup> T cells during thalidomide exposure, returning to basal levels right after thalidomide withdrawal, whereas no specific trends were detected in the control group. The same result was observed in the Thalidomide group with regard to the US-CPR level. Furthermore, the CD4<sup>+</sup> T cell counts decreased during thalidomide use without any changes in the CD8<sup>+</sup> T cell counts, leading to a decrease in the CD4/CD8 ratios, although these levels returned to the baseline ranges immediately following thalidomide withdrawal, thus confirming that these changes were exclusively related to drug exposure. Again, no trends were observed in the control group. Interestingly, no changes in the viral loads were observed in both groups, and no changes were observed in the LPS plasma levels. We then speculated that an HIV viral replication process could be triggered by thalidomide, leading to an increase in inflammation and the death of infected CD4<sup>+</sup> T cells without any apparent disturbance of CD8<sup>+</sup> T cells and without changing the HIV-associated translocation process. As the studied individuals were naturally viremic, we were not able to detect any increase in the viral load levels because untreated individuals are able to produce and eliminate 10 billion HIV virions every day (<xref rid="bb0055" ref-type="bibr">Ho et al., 1995</xref>). However, previous studies using Thalidomide among HIV infected individuals have demonstrated a trend in the increase of HIV viral load after Thalidomide exposure, when this drug was used for oral aphthous ulcers (<xref rid="bb0075" ref-type="bibr">Jacobson et al., 1999</xref>) and HIV wasting syndrome (<xref rid="bb0080" ref-type="bibr">Kaplan et al., 2000</xref>). In another placebo controlled study, 28&#x000a0;days of thalidomide treatment was associated with the modest overshoot in the rebound of viremia, which vanished after stopping the drug (<xref rid="bb0045" ref-type="bibr">Haslett et al., 1999</xref>). Interestingly, one of the individuals recruited in the Thalidomide group was an elite controller, and we detected increased expression of T cell activation markers and an increase in the US-CRP level during thalidomide use followed by a blip of viremia to 67 (1.83 log<sub>10</sub>) copies/mL. We therefore conducted <italic>in vitro</italic> assays to confirm that thalidomide was able to transactivate HIV, by showing that this drug could act as a latency reversal agent. Surprisingly, our preliminary results were unequivocal, showing a very potent latency-reverting effect of thalidomide in samples from 6 out of 7 tested patients. Thalidomide has been associated with inhibition of NF-kB activity through a mechanism that involves the suppression of Inhibitor of kappa kinase (IKK) activity (<xref rid="bb0090" ref-type="bibr">Keifer et al., 2001</xref>). Since kappa kinase cannot phosphorylate the inhibitor, NFKB stays arrested in the cytoplasm and cell activation is halted at this step, which is the alleged mechanism for the anti-inflammatory properties usually seen with Thalidomide (<xref rid="bb0090" ref-type="bibr">Keifer et al., 2001</xref>). For complete T-cell activation, two signals delivered by antigen presenting cells are required: (<italic>i</italic>) T cell receptor binding to its cognate antigen and (<italic>ii</italic>) a co-stimulation signal in which CD28 molecule expressed by T cell binds with CD80/86 molecules expressed by Antigen presenting Cells. Beside suppression of IKK, Thalidomide is also known to co-stimulate T-cells <italic>via</italic> CD28 receptor (<xref rid="bb0040" ref-type="bibr">Haslett et al., 1998</xref>). This effect of Thalidomide could be associated with T-cell activation and increase in HIV replication, which reconciles with our <italic>in vivo</italic> and <italic>ex-vivo</italic> results. In fact, HIV viral load increase has been previously reported upon thalidomide therapy in trials treating oral aphthous ulcers (<xref rid="bb0075" ref-type="bibr">Jacobson et al., 1999</xref>) and HIV wasting syndrome (<xref rid="bb0080" ref-type="bibr">Kaplan et al., 2000</xref>). In another placebo controlled study, 28&#x000a0;days of thalidomide treatment was also associated with the modest overshoot in the rebound of HIV viremia, which vanished after stopping the drug (<xref rid="bb0045" ref-type="bibr">Haslett et al., 1999</xref>).</p><p>In spite of its inflammatory properties, TNF-&#x003b1; production can be a restrictive factor for HIV replication, and it is conceivable that thalidomide use was able to block this process. TNF-&#x003b1; is detected after HIV-1 infection of primary macrophages <italic>in vitro</italic> and is present in plasma and tissues of patients with AIDS (<xref rid="bb0050" ref-type="bibr">Herbein et al., 1996</xref>). <italic>In vitro</italic>, TNF-&#x003b1; is secreted by primary macrophages infected in culture by HIV-1 or treated with envelope glycoprotein gp120 and by HIV-infected monocytes isolated from patients (<xref rid="bb0120" ref-type="bibr">Merrill et al., 1989</xref>). TNF-&#x003b1; is able to enhance host cellular resistance to HIV-1 infection through selective inhibition of HIV-1 entry into primary tissue culture-differentiated macrophages (<xref rid="bb0050" ref-type="bibr">Herbein et al., 1996</xref>). One plausible strategy for the inhibition of HIV entry by TNF-&#x003b1; in macrophages may be through negative modulation of the transcription of CD4 and CCR5, which might explain the inhibition of HIV entry in these permissive cells (<xref rid="bb0085" ref-type="bibr">Karsten et al., 1996</xref>). For this reason, we also monitored the ability of thalidomide to select CXCR4, although no positive results were obtained in the current study. Of note and as mentioned before, we have not been able to find any difference in the cytokine levels between groups or during Thalidomide intake.</p><p>Interestingly, we observed in the Control group that T cell activation slightly and linearly increased over time, even with no changes in the basal viral loads. As seen in other studies, there was a positive correlation between the viral loads and CD4 and CD8 T cell activation levels (<xref rid="bb0060" ref-type="bibr">Hunt et al., 2003</xref>).</p><p>We recognize that the pilot proof-of-concept open-label nature of this study, specifically related to the small sample size of recruited patients, may preclude conclusions that are more definite. Furthermore, the lack of cytokine profile analysis also prevents us from further understanding the mechanisms related to the inflammatory processes documented here. In addition, a comparison group of HIV-uninfected individuals using thalidomide for the same period of time would enable us to further address the specific effects of thalidomide in association to HIV. Nevertheless, our results clearly demonstrated that thalidomide induces a potent inflammatory profile in the presence of HIV, indicating that this drug may serve as an HIV purging tool in the new era of HIV-sterilizing treatment discoveries.</p></sec><sec id="s0110"><title>Trial Registration</title><p>Brazilian agencies #17686/09 and #658/10.</p></sec><sec id="s0115"><title>Funding</title><p><funding-source id="gts0005">FAPESP</funding-source>, grants #04/15856-9.</p></sec><sec id="s0120"><title>Authors' Contributions</title><p>TV: cohort follow-up and manuscript preparation; SS: <italic>in vitro</italic> studies for HIV latency reversal; JS-O: cell activation and LPS assays and statistical analysis; LG: cell activation assays; MSA: HIV genome sequencing and analysis and manuscript preparation; MLS-F: laboratory assistance; LACC: patient inclusion and clinical evaluation; MST: patient inclusion and clinical evaluation; AC: patient inclusion and clinical evaluation; MCS: laboratory supervision; AMC: laboratory supervision, statistical analysis, and manuscript preparation; RSD: study design, data interpretation, and manuscript preparation.</p></sec><sec id="s0125"><title>Conflict of Interest</title><p>The authors have no conflicts of interest to declare.</p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0005"><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name><surname>Bilello</surname><given-names>J.A.</given-names></name><name><surname>Stellrecht</surname><given-names>K.</given-names></name><name><surname>Drusano</surname><given-names>G.L.</given-names></name><name><surname>Stein</surname><given-names>D.S.</given-names></name></person-group><article-title>Soluble tumor necrosis factor-alpha receptor type II (sTNF alpha RII) correlates with human immunodeficiency virus (HIV) RNA copy number in HIV-infected patients</article-title><source>J Infect Dis</source><volume>173</volume><issue>2</issue><year>1996</year><fpage>464</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">8568313</pub-id></element-citation></ref><ref id="bb0010"><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Breen</surname><given-names>E.C.</given-names></name></person-group><article-title>Pro- and anti-inflammatory cytokines in human immunodeficiency virus infection and acquired immunodeficiency syndrome</article-title><source>Pharmacol. Ther.</source><volume>95</volume><issue>3</issue><year>2002</year><fpage>295</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">12243799</pub-id></element-citation></ref><ref id="bb0015"><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Doherty</surname><given-names>S.D.</given-names></name><name><surname>Hsu</surname><given-names>S.</given-names></name></person-group><article-title>Innovative uses of thalidomide</article-title><source>Dermatol. Clin.</source><volume>28</volume><issue>3</issue><year>2010</year><fpage>577</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">20510766</pub-id></element-citation></ref><ref id="bb0020"><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Chevalier</surname><given-names>M.F.</given-names></name><name><surname>Weiss</surname><given-names>L.</given-names></name></person-group><article-title>The split personality of regulatory T cells in HIV infection</article-title><source>Blood</source><volume>121</volume><issue>1</issue><year>2013</year><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">23043072</pub-id></element-citation></ref><ref id="bb0025"><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>d'Ettorre</surname><given-names>G.</given-names></name><name><surname>Paiardini</surname><given-names>M.</given-names></name><name><surname>Ceccarelli</surname><given-names>G.</given-names></name><name><surname>Silvestri</surname><given-names>G.</given-names></name><name><surname>Vullo</surname><given-names>V.</given-names></name></person-group><article-title>HIV-associated immune activation: from bench to bedside</article-title><source>AIDS Res. Hum. Retrovir.</source><volume>27</volume><issue>4</issue><year>2011</year><fpage>355</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">21309730</pub-id></element-citation></ref><ref id="bb0030"><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name><surname>Faustman</surname><given-names>D.</given-names></name><name><surname>Davis</surname><given-names>M.</given-names></name></person-group><article-title>TNF receptor 2 pathway: drug target for autoimmune diseases</article-title><source>Nat. Rev. Drug Discov.</source><volume>9</volume><issue>6</issue><year>2010</year><fpage>482</fpage><lpage>493</lpage><pub-id pub-id-type="pmid">20489699</pub-id></element-citation></ref><ref id="bb0035"><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name><surname>Franks</surname><given-names>M.E.</given-names></name><name><surname>Macpherson</surname><given-names>G.R.</given-names></name><name><surname>Figg</surname><given-names>W.D.</given-names></name></person-group><article-title>Thalidomide</article-title><source>Lancet</source><volume>363</volume><issue>9423</issue><year>2004</year><fpage>1802</fpage><lpage>1811</lpage><pub-id pub-id-type="pmid">15172781</pub-id></element-citation></ref><ref id="bb0040"><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name><surname>Haslett</surname><given-names>P.A.</given-names></name><name><surname>Corral</surname><given-names>L.G.</given-names></name><name><surname>Albert</surname><given-names>M.</given-names></name><name><surname>Kaplan</surname><given-names>G.</given-names></name></person-group><article-title>Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8&#x000a0;+ subset</article-title><source>J. Exp. Med.</source><volume>187</volume><issue>11</issue><year>1998</year><fpage>1885</fpage><lpage>1892</lpage><pub-id pub-id-type="pmid">9607928</pub-id></element-citation></ref><ref id="bb0045"><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name><surname>Haslett</surname><given-names>P.A.</given-names></name><name><surname>Klausner</surname><given-names>J.D.</given-names></name><name><surname>Makonkawkeyoon</surname><given-names>S.</given-names></name></person-group><article-title>Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients</article-title><source>AIDS Res. Hum. Retrovir.</source><volume>15</volume><issue>13</issue><year>1999</year><fpage>1169</fpage><lpage>1179</lpage><pub-id pub-id-type="pmid">10480630</pub-id></element-citation></ref><ref id="bb0050"><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Herbein</surname><given-names>G.</given-names></name><name><surname>Montaner</surname><given-names>L.J.</given-names></name><name><surname>Gordon</surname><given-names>S.</given-names></name></person-group><article-title>Tumor necrosis factor alpha inhibits entry of human immunodeficiency virus type 1 into primary human macrophages: a selective role for the 75-kilodalton receptor</article-title><source>J. Virol.</source><volume>70</volume><issue>11</issue><year>1996</year><fpage>7388</fpage><lpage>7397</lpage><pub-id pub-id-type="pmid">8892857</pub-id></element-citation></ref><ref id="bb0055"><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>D.D.</given-names></name><name><surname>Neumann</surname><given-names>A.U.</given-names></name><name><surname>Perelson</surname><given-names>A.S.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Leonard</surname><given-names>J.M.</given-names></name><name><surname>Markowitz</surname><given-names>M.</given-names></name></person-group><article-title>Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection</article-title><source>Nature</source><volume>373</volume><issue>6510</issue><year>1995</year><fpage>123</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">7816094</pub-id></element-citation></ref><ref id="bb0060"><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>P.W.</given-names></name><name><surname>Martin</surname><given-names>J.N.</given-names></name><name><surname>Sinclair</surname><given-names>E.</given-names></name></person-group><article-title>T cell activation is associated with lower CD4&#x000a0;+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy</article-title><source>J Infect Dis</source><volume>187</volume><issue>10</issue><year>2003</year><fpage>1534</fpage><lpage>1543</lpage><pub-id pub-id-type="pmid">12721933</pub-id></element-citation></ref><ref id="bb0065"><element-citation publication-type="journal" id="rf0065"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>P.W.</given-names></name><name><surname>Deeks</surname><given-names>S.G.</given-names></name><name><surname>Bangsberg</surname><given-names>D.R.</given-names></name></person-group><article-title>The independent effect of drug resistance on T cell activation in HIV infection</article-title><source>AIDS</source><volume>20</volume><issue>5</issue><year>2006</year><fpage>691</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">16514299</pub-id></element-citation></ref><ref id="bb0070"><element-citation publication-type="journal" id="rf0070"><person-group person-group-type="author"><name><surname>Imamichi</surname><given-names>H.</given-names></name><name><surname>Dewar</surname><given-names>R.L.</given-names></name><name><surname>Adelsberger</surname><given-names>J.W.</given-names></name></person-group><article-title>Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>113</volume><issue>31</issue><year>2016</year><fpage>8783</fpage><lpage>8788</lpage><pub-id pub-id-type="pmid">27432972</pub-id></element-citation></ref><ref id="bb0075"><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>J.M.</given-names></name><name><surname>Spritzler</surname><given-names>J.</given-names></name><name><surname>Fox</surname><given-names>L.</given-names></name></person-group><article-title>Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group</article-title><source>J Infect Dis</source><volume>180</volume><issue>1</issue><year>1999</year><fpage>61</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">10353862</pub-id></element-citation></ref><ref id="bb0080"><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>G.</given-names></name><name><surname>Thomas</surname><given-names>S.</given-names></name><name><surname>Fierer</surname><given-names>D.S.</given-names></name></person-group><article-title>Thalidomide for the treatment of AIDS-associated wasting</article-title><source>AIDS Res. Hum. Retrovir.</source><volume>16</volume><issue>14</issue><year>2000</year><fpage>1345</fpage><lpage>1355</lpage><pub-id pub-id-type="pmid">11018854</pub-id></element-citation></ref><ref id="bb0085"><element-citation publication-type="journal" id="rf0085"><person-group person-group-type="author"><name><surname>Karsten</surname><given-names>V.</given-names></name><name><surname>Gordon</surname><given-names>S.</given-names></name><name><surname>Kirn</surname><given-names>A.</given-names></name><name><surname>Herbein</surname><given-names>G.</given-names></name></person-group><article-title>HIV-1 envelope glycoprotein gp120 down-regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor-alpha</article-title><source>Immunology</source><volume>88</volume><issue>1</issue><year>1996</year><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">8707350</pub-id></element-citation></ref><ref id="bb0090"><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name><surname>Keifer</surname><given-names>J.A.</given-names></name><name><surname>Guttridge</surname><given-names>D.C.</given-names></name><name><surname>Ashburner</surname><given-names>B.P.</given-names></name><name><surname>Baldwin</surname><given-names>A.S.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity</article-title><source>J. Biol. Chem.</source><volume>276</volume><issue>25</issue><year>2001</year><fpage>22382</fpage><lpage>22387</lpage><pub-id pub-id-type="pmid">11297551</pub-id></element-citation></ref><ref id="bb0095"><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name><surname>Klausner</surname><given-names>J.D.</given-names></name><name><surname>Makonkawkeyoon</surname><given-names>S.</given-names></name><name><surname>Akarasewi</surname><given-names>P.</given-names></name></person-group><article-title>The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection</article-title><source>J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.</source><volume>11</volume><issue>3</issue><year>1996</year><fpage>247</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">8603261</pub-id></element-citation></ref><ref id="bb0100"><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name><surname>Lavigne</surname><given-names>S.</given-names></name><name><surname>Santos</surname><given-names>C.</given-names></name><name><surname>Arif</surname><given-names>M.S.</given-names></name></person-group><article-title>Short communication: HIV type 1 tropism determination in a novel dried blood spot membrane and the use of a mixture of outer nested polymerase chain reaction primers</article-title><source>AIDS Res. Hum. Retrovir.</source><volume>30</volume><issue>2</issue><year>2014</year><fpage>147</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">24111560</pub-id></element-citation></ref><ref id="bb0105"><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name><surname>Marchetti</surname><given-names>G.</given-names></name><name><surname>Tincati</surname><given-names>C.</given-names></name><name><surname>Silvestri</surname><given-names>G.</given-names></name></person-group><article-title>Microbial translocation in the pathogenesis of HIV infection and AIDS</article-title><source>Clin. Microbiol. Rev.</source><volume>26</volume><issue>1</issue><year>2013</year><fpage>2</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">23297256</pub-id></element-citation></ref><ref id="bb0110"><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name><surname>Marriott</surname><given-names>J.B.</given-names></name><name><surname>Clarke</surname><given-names>I.A.</given-names></name><name><surname>Dredge</surname><given-names>K.</given-names></name><name><surname>Muller</surname><given-names>G.</given-names></name><name><surname>Stirling</surname><given-names>D.</given-names></name><name><surname>Dalgleish</surname><given-names>A.G.</given-names></name></person-group><article-title>Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells</article-title><source>Clin. Exp. Immunol.</source><volume>130</volume><issue>1</issue><year>2002</year><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">12296856</pub-id></element-citation></ref><ref id="bb0115"><element-citation publication-type="journal" id="rf0115"><person-group person-group-type="author"><name><surname>McMichael</surname><given-names>A.J.</given-names></name><name><surname>Borrow</surname><given-names>P.</given-names></name><name><surname>Tomaras</surname><given-names>G.D.</given-names></name><name><surname>Goonetilleke</surname><given-names>N.</given-names></name><name><surname>Haynes</surname><given-names>B.F.</given-names></name></person-group><article-title>The immune response during acute HIV-1 infection: clues for vaccine development</article-title><source>Nat. Rev. Immunol.</source><volume>10</volume><issue>1</issue><year>2010</year><fpage>11</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">20010788</pub-id></element-citation></ref><ref id="bb0120"><element-citation publication-type="journal" id="rf0120"><person-group person-group-type="author"><name><surname>Merrill</surname><given-names>J.E.</given-names></name><name><surname>Koyanagi</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>I.S.</given-names></name></person-group><article-title>Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor</article-title><source>J. Virol.</source><volume>63</volume><issue>10</issue><year>1989</year><fpage>4404</fpage><lpage>4408</lpage><pub-id pub-id-type="pmid">2789293</pub-id></element-citation></ref><ref id="bb0125"><element-citation publication-type="journal" id="rf0125"><person-group person-group-type="author"><name><surname>Moreira</surname><given-names>A.L.</given-names></name><name><surname>Sampaio</surname><given-names>E.P.</given-names></name><name><surname>Zmuidzinas</surname><given-names>A.</given-names></name><name><surname>Frindt</surname><given-names>P.</given-names></name><name><surname>Smith</surname><given-names>K.A.</given-names></name><name><surname>Kaplan</surname><given-names>G.</given-names></name></person-group><article-title>Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation</article-title><source>J. Exp. Med.</source><volume>177</volume><issue>6</issue><year>1993</year><fpage>1675</fpage><lpage>1680</lpage><pub-id pub-id-type="pmid">8496685</pub-id></element-citation></ref><ref id="bb0130"><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name><surname>Mu</surname><given-names>H.</given-names></name><name><surname>Chai</surname><given-names>H.</given-names></name><name><surname>Lin</surname><given-names>P.H.</given-names></name><name><surname>Yao</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name></person-group><article-title>Current update on HIV-associated vascular disease and endothelial dysfunction</article-title><source>World J. Surg.</source><volume>31</volume><issue>4</issue><year>2007</year><fpage>632</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">17372667</pub-id></element-citation></ref><ref id="bb0135"><element-citation publication-type="journal" id="rf0135"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>S.</given-names></name></person-group><article-title>Advances in detection and monitoring of plasma viremia in HIV-infected individuals receiving antiretroviral therapy</article-title><source>Curr. Opin. HIV AIDS</source><volume>8</volume><issue>2</issue><year>2013</year><fpage>87</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">23314906</pub-id></element-citation></ref><ref id="bb0140"><element-citation publication-type="journal" id="rf0140"><person-group person-group-type="author"><name><surname>Pomerantz</surname><given-names>R.J.</given-names></name><name><surname>Feinberg</surname><given-names>M.B.</given-names></name><name><surname>Trono</surname><given-names>D.</given-names></name><name><surname>Baltimore</surname><given-names>D.</given-names></name></person-group><article-title>Lipopolysaccharide is a potent monocyte/macrophage-specific stimulator of human immunodeficiency virus type 1 expression</article-title><source>J. Exp. Med.</source><volume>172</volume><issue>1</issue><year>1990</year><fpage>253</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">2193097</pub-id></element-citation></ref><ref id="bb0145"><element-citation publication-type="journal" id="rf0145"><person-group person-group-type="author"><name><surname>Poveda</surname><given-names>E.</given-names></name><name><surname>Paredes</surname><given-names>R.</given-names></name><name><surname>Moreno</surname><given-names>S.</given-names></name></person-group><article-title>Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists</article-title><source>AIDS Rev.</source><volume>14</volume><issue>3</issue><year>2012</year><fpage>208</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">22833064</pub-id></element-citation></ref><ref id="bb0150"><element-citation publication-type="journal" id="rf0150"><person-group person-group-type="author"><name><surname>Reeves</surname><given-names>R.K.</given-names></name></person-group><article-title>Mechanisms, consequences, and treatment of chronic inflammation in HIV disease</article-title><source>J Antivir Antiretrovir.</source><volume>06</volume><issue>02</issue><year>2014</year><fpage>xxxvi</fpage><lpage>xxxvii</lpage></element-citation></ref><ref id="bb0155"><element-citation publication-type="journal" id="rf0155"><person-group person-group-type="author"><name><surname>Sampaio</surname><given-names>E.P.</given-names></name><name><surname>Kaplan</surname><given-names>G.</given-names></name><name><surname>Miranda</surname><given-names>A.</given-names></name></person-group><article-title>The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum</article-title><source>J Infect Dis</source><volume>168</volume><issue>2</issue><year>1993</year><fpage>408</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">8335978</pub-id></element-citation></ref><ref id="bb0160"><element-citation publication-type="journal" id="rf0160"><person-group person-group-type="author"><name><surname>Signorelli</surname><given-names>S.S.</given-names></name><name><surname>Mazzarino</surname><given-names>M.C.</given-names></name><name><surname>Spandidos</surname><given-names>D.A.</given-names></name><name><surname>Malaponte</surname><given-names>G.</given-names></name></person-group><article-title>Proinflammatory circulating molecules in peripheral arterial disease</article-title><source>Int. J. Mol. Med.</source><volume>20</volume><issue>3</issue><year>2007</year><fpage>279</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">17671730</pub-id></element-citation></ref><ref id="bb0165"><element-citation publication-type="journal" id="rf0165"><person-group person-group-type="author"><name><surname>Teo</surname><given-names>S.</given-names></name><name><surname>Resztak</surname><given-names>K.E.</given-names></name><name><surname>Scheffler</surname><given-names>M.A.</given-names></name></person-group><article-title>Thalidomide in the treatment of leprosy</article-title><source>Microbes Infect.</source><volume>4</volume><issue>11</issue><year>2002</year><fpage>1193</fpage><lpage>1202</lpage><pub-id pub-id-type="pmid">12361920</pub-id></element-citation></ref><ref id="bb0170"><element-citation publication-type="journal" id="rf0170"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.Y.</given-names></name><name><surname>Guttridge</surname><given-names>D.C.</given-names></name><name><surname>Mayo</surname><given-names>M.W.</given-names></name><name><surname>Baldwin</surname><given-names>A.S.</given-names><suffix>Jr.</suffix></name></person-group><article-title>NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis</article-title><source>Mol. Cell. Biol.</source><volume>19</volume><issue>9</issue><year>1999</year><fpage>5923</fpage><lpage>5929</lpage><pub-id pub-id-type="pmid">10454539</pub-id></element-citation></ref></ref-list><sec id="s0130" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary Data</title><p><supplementary-material content-type="local-data" id="ec0005"><caption><p>Supplementary tables</p></caption><media xlink:href="mmc1.docx"><alt-text>Image 1</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="ec0010"><caption><p>Supplementary figures</p></caption><media xlink:href="mmc2.doc"><alt-text>Image 2</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="ec0015"><caption><p>Supplementary material</p></caption><media xlink:href="mmc3.docx"><alt-text>Image 3</alt-text></media></supplementary-material></p></sec><fn-group><fn id="s0135" fn-type="supplementary-material"><label>Appendix A</label><p>Supplementary data to this article can be found online at <ext-link ext-link-type="doi" xlink:href="10.1016/j.ebiom.2017.08.007" id="ir0015">http://dx.doi.org/10.1016/j.ebiom.2017.08.007</ext-link>.</p></fn></fn-group></back></article>